Inhibition of Monoacylglycerol Lipase by NSD1819 as an Effective Strategy for the Endocannabinoid System Modulation against Neuroinflammation-Related Disorders.
2-AG
LPS
MGL inhibitor
depression
glial cells
memory
neuroinflammation
pain
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
received:
20
06
2022
revised:
22
07
2022
accepted:
26
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Neuroinflammation is a key pathological event shared by different diseases affecting the nervous system. Since the underlying mechanism of neuroinflammation is a complex and multifaceted process, current pharmacological treatments are unsatisfactory-a reason why new therapeutic approaches are mandatory. In this context, the endocannabinoid system has proven to possess neuroprotective and immunomodulatory actions under neuroinflammatory status, and its modulation could represent a valuable approach to address different inflammatory processes. To this aim, we evaluated the efficacy of a repeated treatment with NSD1819, a potent β-lactam-based monoacylglycerol lipase inhibitor in a mouse model of neuroinflammation induced by lipopolysaccharide (LPS) injection. Mice were intraperitoneally injected with LPS 1 mg/kg for five consecutive days to induce systemic inflammation. Concurrently, NSD1819 (3 mg/kg) was daily per os administered from day 1 until the end of the experiment (day 11). Starting from day 8, behavioral measurements were performed to evaluate the effect of the treatment on cognitive impairments, allodynia, motor alterations, anhedonia, and depressive-like behaviors evoked by LPS. Histologically, glial analysis of the spinal cord was also performed. The administration of NSD1819 was able to completely counteract thermal and mechanical allodynia as highlighted by the Cold plate and von Frey tests, respectively, and to reduce motor impairments as demonstrated by the Rota rod test. Moreover, the compound was capable of neutralizing the memory loss in the Passive avoidance test, and reducing depressive-like behavior in the Porsolt test. Finally, LPS stimulation caused a significant glial cells activation in the dorsal horn of the lumbar spinal cord that was significantly recovered by NSD1819 repeated treatment. In conclusion, NSD1819 was able to thwart the plethora of symptoms evoked by LPS, thus representing a promising candidate for future applications in the context of neuroinflammation and related diseases.
Identifiants
pubmed: 35955562
pii: ijms23158428
doi: 10.3390/ijms23158428
pmc: PMC9369272
pii:
doi:
Substances chimiques
Endocannabinoids
0
Lipopolysaccharides
0
Monoacylglycerol Lipases
EC 3.1.1.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of University and Research
ID : not available
Références
J Neuroendocrinol. 2008 May;20 Suppl 1:10-4
pubmed: 18426493
Neuropsychopharmacology. 2008 Sep;33(10):2341-51
pubmed: 18075491
Neuroscience. 2014 Aug 22;274:209-17
pubmed: 24875177
ChemMedChem. 2020 Nov 4;15(21):1985-2003
pubmed: 32762071
Neurotherapeutics. 2020 Jul;17(3):1005-1015
pubmed: 32572830
Psychol Trauma. 2020 Aug;12(S1):S66
pubmed: 32496094
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986
J Neurochem. 2017 Sep;142(5):624-648
pubmed: 28608560
Exp Neurol. 2012 Apr;234(2):362-72
pubmed: 22036747
Ann Neurol. 2013 Jul;74(1):1-3
pubmed: 23686675
Brain. 2021 Jul 28;144(6):1869-1883
pubmed: 33723589
Front Pharmacol. 2022 Feb 04;12:806417
pubmed: 35185547
FASEB J. 2005 Aug;19(10):1329-31
pubmed: 15919760
Nature. 2005 Jun 23;435(7045):1108-12
pubmed: 15973410
BMC Psychiatry. 2020 Oct 20;20(1):511
pubmed: 33081741
Brain Behav Immun. 2008 Mar;22(3):301-11
pubmed: 17951027
Biomolecules. 2021 Oct 02;11(10):
pubmed: 34680083
Future Med Chem. 2009 Oct;1(7):1333-49
pubmed: 20191092
Biol Psychiatry. 2016 Apr 1;79(7):516-25
pubmed: 26698193
Pharmacol Biochem Behav. 2015 Jan;128:1-7
pubmed: 25449357
Pharmacol Rev. 2006 Sep;58(3):389-462
pubmed: 16968947
J Immunol. 2011 Dec 15;187(12):6508-17
pubmed: 22079984
Expert Rev Proteomics. 2013 Feb;10(1):43-63
pubmed: 23414359
Curr Neuropharmacol. 2012 Jun;10(2):159-66
pubmed: 23204985
Clin Immunol. 2012 Jan;142(1):57-67
pubmed: 21420365
Nature. 1977 Apr 21;266(5604):730-2
pubmed: 559941
Front Neurol. 2020 Feb 14;11:87
pubmed: 32117037
Exp Neurol. 2014 Nov;261:22-33
pubmed: 24967684
CNS Neurol Disord Drug Targets. 2016;15(9):1072-1078
pubmed: 27573801
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8268-73
pubmed: 9653176
Acta Neurobiol Exp (Wars). 2016;76(4):257-268
pubmed: 28094817
Curr Neuropharmacol. 2007;5(2):73-80
pubmed: 18615177
Curr Opin Immunol. 2000 Feb;12(1):20-6
pubmed: 10679411
J Neurochem. 2016 Oct;139 Suppl 2:136-153
pubmed: 26990767
J Am Chem Soc. 2007 Aug 8;129(31):9594-5
pubmed: 17629278
Psychol Rep. 1967 Aug;21(1):221-4
pubmed: 6078370
Brain Behav Immun. 2022 May;102:89-97
pubmed: 35181440
J Psychiatr Res. 2022 May;149:367-373
pubmed: 34809994
Biomed Res Int. 2017;2017:5071786
pubmed: 29181395
Br J Pharmacol. 2008 Jan;153(2):240-51
pubmed: 18037916
Crit Care Med. 2002 Mar;30(3):548-54
pubmed: 11990913
Neurobiol Aging. 2005 Mar;26(3):349-54
pubmed: 15639313
Drug Discov Today. 2014 Mar;19(3):295-304
pubmed: 23891880
Oxid Med Cell Longev. 2014;2014:893516
pubmed: 25136404
Handb Exp Pharmacol. 2005;(168):327-65
pubmed: 16596780
Nature. 1998 Jul 16;394(6690):277-81
pubmed: 9685157
J Neurosci. 2002 Apr 1;22(7):2478-86
pubmed: 11923412
Mol Pain. 2014 May 20;10:29
pubmed: 24886406
Cancer Chemother Pharmacol. 2017 Dec;80(6):1091-1103
pubmed: 29026967
Environ Health Perspect. 2003 Jun;111(8):1065-73
pubmed: 12826478
Front Pharmacol. 2020 Sep 18;11:576624
pubmed: 33071790
Eur J Pharmacol. 2014 Jul 15;735:141-9
pubmed: 24786153
Bioorg Med Chem Lett. 2013 Jan 15;23(2):492-5
pubmed: 23237837
Physiol Rev. 2002 Oct;82(4):981-1011
pubmed: 12270950
Prog Lipid Res. 2018 Jul;71:1-17
pubmed: 29751000
J Neuroinflammation. 2015 Jan 20;12:10
pubmed: 25600429
J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):297-302
pubmed: 26669245
Br J Anaesth. 2013 Jul;111(1):26-37
pubmed: 23794642
J Neurol. 2021 Aug;268(8):2671-2675
pubmed: 33030607
ChemMedChem. 2018 Oct 8;13(19):2090-2103
pubmed: 30085402
Int J Mol Sci. 2018 Sep 27;19(10):
pubmed: 30262747
J Med Chem. 2016 Mar 24;59(6):2612-32
pubmed: 26888301
Brain Res. 2011 May 16;1390:126-41
pubmed: 21406188
Phytother Res. 2020 Sep;34(9):2331-2340
pubmed: 32236999
Pain. 2009 Dec 15;147(1-3):165-74
pubmed: 19782472
J Neurochem. 2012 Apr;121(1):4-27
pubmed: 22251135